DOCSLIB.ORG

Thesis Template

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Thesis Template An investigation into the effect of DNA structural polymorphism and single-stranded DNA binding proteins on repair of disease-associated slipped-DNA repeats by Jennifer Jing Luo A thesis submitted in conformity with the requirements for the degree of Master of Science Molecular Genetics University of Toronto © Copyright by Jennifer Jing Luo 2015 An investigation into the effect of DNA structural polymorphism and single-stranded DNA binding proteins on repair of disease- associated slipped-DNA repeats Jennifer Jing Luo Master of Science Molecular Genetics University of Toronto 2015 Abstract Gene-specific repeat expansions are the cause of a growing list of neurological diseases, including myotonic dystrophy type 1 and Huntington's disease. The formation of slipped-DNA structures in the expanded repeat sequences is thought to drive repeat instability and pathogenesis by impairing normal DNA metabolic processes. Here I show that slipped-DNAs with nicks located within the repeat tract displayed increased structural heterogeneity relative to slipped-DNAs with nicks located in the flanking sequence. Nick-in-repeat slipped-DNAs were repaired better than nick-in-flank slipped-DNAs, likely due to increased amounts of single- stranded DNA at the nicked repeat ends allowing for better repair factor binding. Single-stranded DNA binding proteins RPA and aRPA seem to play an important part in tissue-specific instability as both complexes are overexpressed in the brains of HD patients. Neither RPA nor aRPA was required for slipped-DNA repair, although they both enhanced slipped-DNA repair efficiency. ii Acknowledgments I would like to thank my supervisor Dr. Christopher Pearson for his guidance, enthusiasm and encouragement over the years. I have learned much about science and life in your lab and I will always be grateful for the opportunities that you have given me. I would like to thank my committee members, Dr. David Bazett-Jones and Dr. Irene Andrulis, for the much-appreciated advice and feedback that you have always given me. I would like to thank our collaborators, especially Dr. Marc Wold, who has provided valuable resources and expertise for my project. A big thank you for all the members of the Pearson lab, both past and present, for the help and support you have given me. I am so grateful that I had such wonderful colleagues to depend on, to turn to for help, and most importantly I am grateful for the laughs. I would like to thank all of my GGB and Mol Gen friends who all contributed to make my graduate school experience a fun and productive one. Thank you to my friends and family who gave me love, support and encouragement. Thank you to my parents, Hui Luo and Aishe Sun. I am so grateful for everything that you have given me and all the sacrifices you have made for me. I hope to make you proud in everything I do. Thank you to Petro, the best partner-in-life I could ask for. Thank you for your love and support. Thank you for feeding me when I forget to eat. Thank you for making me sleep when work becomes all-consuming. Thank you for the walks and the heated debates. Most importantly, thank you for making me want to be better in everything I do. iii Table of Contents Acknowledgments .......................................................................................................................... iii List of Tables ................................................................................................................................ vii List of Figures .............................................................................................................................. viii List of Abbreviations ..................................................................................................................... ix 1 Introduction ................................................................................................................................ 1 1.1 Disease-causing trinucleotide repeats ................................................................................. 1 1.2 Pathogenic mechanisms in trinucleotide repeat diseases .................................................... 3 1.2.1 Gain of toxic protein function: Huntington’s disease ............................................. 3 1.2.2 Gain of toxic RNA function: myotonic dystrophy type 1 ....................................... 5 1.3 DNA structures and repeat instability ................................................................................. 6 1.3.1 CTG/CAG slipped-DNA ........................................................................................ 7 1.4 Mechanisms of repeat instability ........................................................................................ 9 1.4.1 DNA repair and repeat instability ......................................................................... 11 1.4.2 DNA replication and repeat instability ................................................................. 14 1.5 Replication protein A: eukaryotic singled-stranded DNA binding protein ...................... 16 1.5.1 RPA in DNA replication ....................................................................................... 16 1.5.2 RPA in nucleotide excision repair ........................................................................ 17 1.5.3 RPA in base excision repair .................................................................................. 17 1.5.4 RPA in mismatch repair ........................................................................................ 18 1.5.5 An alternative form of RPA: aRPA ...................................................................... 18 1.6 Thesis Goals ...................................................................................................................... 19 2 Effect of DNA structural hyper-polymorphism and single-stranded DNA binding proteins on repair of disease-associated slipped-DNA repeats .............................................................. 22 2.1 Introduction ....................................................................................................................... 22 2.2 Materials and Methods ...................................................................................................... 25 iv 2.2.1 Slipped-intermediate DNA (SI-DNA) substrate preparation ................................ 25 2.2.2 Human cell extract preparation ............................................................................. 26 2.2.3 SV40 DNA replication .......................................................................................... 27 2.2.4 In vitro DNA repair ............................................................................................... 27 2.2.5 Western blotting .................................................................................................... 28 2.2.6 DNA binding assays ............................................................................................. 29 2.3 Results ............................................................................................................................... 29 2.3.1 Slipped-DNAs with increased single-stranded potential ...................................... 29 2.3.2 RPA4 expression is elevated above RPA2 in HD patient brains .......................... 38 2.3.3 RPA and aRPA can enhance slipped-DNA repair ................................................ 40 2.3.4 Repair is nick-directed .......................................................................................... 45 2.3.5 Yeast RPA and bacterial SSB cannot substitute for human RPA in enhancing repair ..................................................................................................................... 48 2.3.6 Inhibition of slipped-DNA repair by high concentrations of aRPA ..................... 50 2.3.7 RPA is limiting for the repair of nick-in-repeat slipped-DNAs, this effect is independent of MutSβ ........................................................................................... 53 2.3.8 FEN1 is not required for slipped-DNA repair ...................................................... 56 2.3.9 RPA and aRPA bind to and melt slipped-DNAs differently ................................ 59 2.4 Conclusions and Discussion ............................................................................................. 63 2.4.1 Nick-in-repeat slip-outs have greater structural heterogeneity than nick-in- flank slip-outs ........................................................................................................ 63 2.4.2 Nick-in-repeat slip-outs are better repaired .......................................................... 63 2.4.3 RPA and aRPA can enhance slipped-DNA repair ................................................ 65 2.4.4 Inhibition of slipped-DNA repair by high concentrations of aRPA ..................... 67 2.4.5 Repair of large slipped-DNAs is independent of MMR and BER ........................ 68 2.4.6 MMR does not require RPA ................................................................................. 69 2.4.7 RPA and aRPA bind to and denature slipped-DNAs differently .......................... 69 v 2.4.8 aRPA function ....................................................................................................... 70 3 Summary and future directions ................................................................................................ 72 3.1 Thesis summary ...............................................................................................................
Load more

Recommended publications
  • WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/174282 A2 20 December 2012 (20.12.2012) P O P C T (51) International Patent Classification: David [US/US]; 13539 N . 95th Way, Scottsdale, AZ C12Q 1/68 (2006.01) 85260 (US). (21) International Application Number: (74) Agent: AKHAVAN, Ramin; Caris Science, Inc., 6655 N . PCT/US20 12/0425 19 Macarthur Blvd., Irving, TX 75039 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 14 June 2012 (14.06.2012) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, English (25) Filing Language: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (30) Priority Data: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 61/497,895 16 June 201 1 (16.06.201 1) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 61/499,138 20 June 201 1 (20.06.201 1) US OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, 61/501,680 27 June 201 1 (27.06.201 1) u s SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, 61/506,019 8 July 201 1(08.07.201 1) u s TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
    [Show full text]
  • Differential Mechanisms of Tolerance to Extreme Environmental
    www.nature.com/scientificreports OPEN Diferential mechanisms of tolerance to extreme environmental conditions in tardigrades Dido Carrero*, José G. Pérez-Silva , Víctor Quesada & Carlos López-Otín * Tardigrades, also known as water bears, are small aquatic animals that inhabit marine, fresh water or limno-terrestrial environments. While all tardigrades require surrounding water to grow and reproduce, species living in limno-terrestrial environments (e.g. Ramazzottius varieornatus) are able to undergo almost complete dehydration by entering an arrested state known as anhydrobiosis, which allows them to tolerate ionic radiation, extreme temperatures and intense pressure. Previous studies based on comparison of the genomes of R. varieornatus and Hypsibius dujardini - a less tolerant tardigrade - have pointed to potential mechanisms that may partially contribute to their remarkable ability to resist extreme physical conditions. In this work, we have further annotated the genomes of both tardigrades using a guided approach in search for novel mechanisms underlying the extremotolerance of R. varieornatus. We have found specifc amplifcations of several genes, including MRE11 and XPC, and numerous missense variants exclusive of R. varieornatus in CHEK1, POLK, UNG and TERT, all of them involved in important pathways for DNA repair and telomere maintenance. Taken collectively, these results point to genomic features that may contribute to the enhanced ability to resist extreme environmental conditions shown by R. varieornatus. Tardigrades are small
    [Show full text]
  • Full Text (PDF)
    medRxiv preprint doi: https://doi.org/10.1101/2020.12.29.20248986; this version posted January 4, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Insights into the molecular mechanism of anticancer drug ruxolitinib repurposable in COVID-19 therapy Manisha Mandal Department of Physiology, MGM Medical College, Kishanganj-855107, India Email: [email protected], ORCID: https://orcid.org/0000-0002-9562-5534 Shyamapada Mandal* Department of Zoology, University of Gour Banga, Malda-732103, India Email: [email protected], ORCID: https://orcid.org/0000-0002-9488-3523 *Corresponding author: Email: [email protected]; [email protected] Abstract Due to non-availability of specific therapeutics against COVID-19, repurposing of approved drugs is a reasonable option. Cytokines imbalance in COVID-19 resembles cancer; exploration of anti-inflammatory agents, might reduce COVID-19 mortality. The current study investigates the effect of ruxolitinib treatment in SARS-CoV-2 infected alveolar cells compared to the uninfected one from the GSE5147507 dataset. The protein-protein interaction network, biological process and functional enrichment of differentially expressed genes were studied using STRING App of the Cytoscape software and R programming tools. The present study indicated that ruxolitinib treatment elicited similar response equivalent to that of SARS-CoV-2 uninfected situation by inducing defense response in host against virus infection by RLR and NOD like receptor pathways. Further, the effect of ruxolitinib in SARS- CoV-2 infection was mainly caused by significant suppression of IFIH1, IRF7 and MX1 genes as well as inhibition of DDX58/IFIH1-mediated induction of interferon- I and -II signalling.
    [Show full text]
  • Epigenetic Screen of Human DNA Repair Genes Identifies Aberrant
    Oncogene (2012) 31, 5108 --5116 & 2012 Macmillan Publishers Limited All rights reserved 0950-9232/12 www.nature.com/onc ORIGINAL ARTICLE Epigenetic screen of human DNA repair genes identifies aberrant promoter methylation of NEIL1 in head and neck squamous cell carcinoma J Chaisaingmongkol1, O Popanda1,RWarta2,3, G Dyckhoff2, E Herpel4, L Geiselhart1, R Claus1, F Lasitschka5, B Campos3, CC Oakes1, JL Bermejo6, C Herold-Mende2,3, C Plass1 and P Schmezer1 Aberrant promoter methylation of different DNA repair genes has a critical role in the development and progression of various cancer types, including head and neck squamous cell carcinomas (HNSCCs). A systematic analysis of known human repair genes for promoter methylation is however missing. We generated quantitative promoter methylation profiles in single CpG units of 160 human DNA repair genes in a set of DNAs isolated from fresh frozen HNSCC and normal tissues using MassARRAY technology. Ninety-eight percent of these genes contained CpG islands (CGIs) in their promoter region; thus, DNA methylation is a potential regulatory mechanism. Methylation data were obtained for 145 genes, from which 15 genes exhibited more than a 20% difference in methylation levels between tumor and normal tissues, manifested either as hypermethylation or as hypomethylation. Analyses of promoter methylation with mRNA expression identified the DNA glycosylase NEIL1 (nei endonuclease VIII-like 1) as the most prominent candidate gene. NEIL1 promoter hypermethylation was confirmed in additional fresh frozen HNSCC samples, normal mucosa, HNSCC cell lines and primary human skin keratinocytes. The investigation of laser-microdissected tissues further substantiated increased methylation levels in tumor versus matched non-tumor cells.
    [Show full text]
  • Glatiramer Acetate Treatment Effects on Gene Expression in Monocytes of Multiple Sclerosis Patients
    Thamilarasan et al. Journal of Neuroinflammation 2013, 10:126 JOURNAL OF http://www.jneuroinflammation.com/content/10/1/126 NEUROINFLAMMATION RESEARCH Open Access Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients Madhan Thamilarasan1,2†, Michael Hecker1,2*†, Robert Hermann Goertsches1,2, Brigitte Katrin Paap2, Ina Schröder2, Dirk Koczan1, Hans-Jürgen Thiesen1 and Uwe Klaus Zettl2 Abstract Background: Glatiramer acetate (GA) is a mixture of synthetic peptides used in the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The aim of this study was to investigate the effects of GA therapy on the gene expression of monocytes. Methods: Monocytes were isolated from the peripheral blood of eight RRMS patients. The blood was obtained longitudinally before the start of GA therapy as well as after one day, one week, one month and two months. Gene expression was measured at the mRNA level by microarrays. Results: More than 400 genes were identified as up-regulated or down-regulated in the course of therapy, and we analyzed their biological functions and regulatory interactions. Many of those genes are known to regulate lymphocyte activation and proliferation, but only a subset of genes was repeatedly differentially expressed at different time points during treatment. Conclusions: Overall, the observed gene regulatory effects of GA on monocytes were modest and not stable over time. However, our study revealed several genes that are worthy of investigation in future studies on the molecular mechanisms of GA therapy. Keywords: Glatiramer acetate, Relapsing-remitting multiple sclerosis, Monocytes, Gene expression profiling, Microarray analysis Background GA (copolymer 1) is a first-line treatment option for Multiple sclerosis (MS) is a chronic immune-mediated RRMS.
    [Show full text]
  • Cord Blood DNA Methylome in Newborns Later Diagnosed with Autism Spectrum Disorder
    bioRxiv preprint doi: https://doi.org/10.1101/850529; this version posted November 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. 1 Cord blood DNA methylome in newborns later diagnosed with autism spectrum disorder reflects early dysregulation of neurodevelopmental and X-linked genes Charles E. Mordaunt1 [email protected] Julia M. Jianu1 [email protected] Ben Laufer1 [email protected] Yihui Zhu1 [email protected] Keith W. Dunaway1 [email protected] Kelly M. Bakulski2 [email protected] Jason I. Feinberg3 [email protected] Heather E. Volk3 [email protected] Kristen Lyall4 [email protected] Lisa A. Croen5 [email protected] Craig J. Newschaffer6 [email protected] Sally Ozonoff7 [email protected] Irva Hertz-Picciotto8 [email protected] M. Daniele Fallin3 [email protected] Rebecca J. Schmidt8 [email protected] Janine M. LaSalle1* [email protected] *Corresponding author 1. Department of Medical Microbiology and Immunology, Genome Center, and MIND Institute, University of California, Davis, CA, USA 2. Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA 3. Wendy Klag Center for Autism and Developmental Disabilities, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA bioRxiv preprint doi: https://doi.org/10.1101/850529; this version posted November 21, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity.
    [Show full text]
  • Supplemental Figures
    Control #1 Control #2 Control #3 83972 #1 83972 #2 83972 #3 CFT073 #1 CFT073 #2 CFT073 #3 Log-intensity ratios (M-values) ratios Log-intensity Log-intensity averages (A-values) Supplemental Figure 1. MA-plots showing normalized raw data using cross- correlation. The data was found to be of high quality with high replicate correlation (correlation>0.98) and with no systematic bias. A 83972 B CFT073 Supplemental Figure 2. Inversely regulated gene networks generated by IPA. The five inversely regulated genes belonged to one functional network in which HSPA6, FOSB and RN7SK interact with TATA box binding protein (TBP), a general transcription factor required for RNA polymerase II activity. The ABU strain 83972 (A) suppressed FOSB and other genes in this network while the CFT073 strain (B) enhanced their expression. 83972 also suppressed RGS4, a negative regulator of G-protein-coupled receptor-induced signaling and IFIT1, a gene of the type I IFN signaling pathway essential for the antibacterial effector response. A No of affected Network genes Score Top functions genes BAIAP2, BANP, BRIX1, Caspase, CTNNB1, Cyclin A, DACH1, Infection Mechanisms, EMP1, EPHA4, FGFBP1, GADD45G, HES1, HIST2H2BE, IgG, Infectious Disease, IL12, Interferon α, Jnk, MAVS, MDM2, NFkB, NOD1, P38 MAPK, 51 24 Endocrine System PDCD4, PELI2, PEMT, Ras homolog, TFAP2A, TLR5, Development and TNFRSF10D, UBC, Ubiquitin, VANGL2, VARS, Vegf, ZC3HAV1 Function AHCTF1, AKR1C2, ALOX5AP, ARL4A, BAMBI, BAZ2B, Bcl9- Cbp/p300-Ctnnb1-Lef/Tcf, BRF2, CA9, Ca2+, CNN2, CRIP1, Small Molecule
    [Show full text]
  • Microrna and Messengerrna Expression Changes During Interferon-Beta and Glatiramer Acetate Treatment in Peripheral Blood Cells of Multiple Sclerosis Patients
    University of Rostock Department of Neurology Director: Prof. Dr. Reiner Benecke Neuroimmunology section Chair: Prof. Dr. Uwe Klaus Zettl MicroRNA and MessengerRNA Expression Changes during Interferon-beta and Glatiramer Acetate Treatment in Peripheral Blood Cells of Multiple Sclerosis Patients Dissertation To obtain the Academic Degree of Doctor rerum humanarum (Dr. rer. hum.) Faculty of Medicine, University of Rostock Madhan Thamilarasan 17.07.1981, Sivaganga, Tamil Nadu, India Rostock, 2014 Reviewer: 1. Reviewer: Prof. Dr. med. Uwe Klaus Zettl Department of Neurology, University of Rostock 2. Reviewer: Prof. Dr. med. Friedemann Paul NeuroCure Clinical Research Center, Charité, Berlin 3. Reviewer: Dr. med. Jürgen Faiss Department of Neurology, Asklepios Klinikum Teupitz Date of submission: 14. March 2014 Date of defense: 11. March 2015 Table of contents Abbreviations . 1 1. Introduction . 3 1.1 Glatiramer acetate . 7 1.2 Interferon-beta . 9 1.3 MicroRNA in multiple sclerosis . 10 2. Aims and objectives . 13 3. Materials and methods . 16 3.1 Study population and blood sample collection . 16 3.2 Cell isolation, RNA and miRNA preparation and gene expression profiling . 16 3.3 Data analysis and databases . 17 3.4 Gene Ontology analysis . 18 3.5 Molecular network analysis . 18 4. Results . 20 4.1 Differentially expressed genes and microRNAs . 20 4.2 Gene interaction network analysis . 25 5. Discussion . 27 6. Summary . 33 7. References . 36 8. Publications . 45 8.1 Manuscript - 1. 45 Glatiramer acetate treatment effects on gene expression in monocytes of multiple sclerosis patients. Thamilarasan M, Hecker M, Goertsches RH, Paap BK, Schröder I, Koczan D, Thiesen HJ, Zettl UK.
    [Show full text]
  • Neoadjuvant Chemoradiation Alters Biomarkers of Anticancer Immunotherapy Responses in Locally Advanced Rectal Cancer
    Open access Original research J Immunother Cancer: first published as 10.1136/jitc-2020-001610 on 10 March 2021. Downloaded from Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer 1 2,3 4 2,5 Incheol Seo, Hye Won Lee, Sang Jun Byun , Jee Young Park, 5 6,7 7 5,7,8 Hyeonji Min, Sung Hwan Lee , Ju- Seog Lee, Shin Kim , Sung Uk Bae8,9 To cite: Seo I, Lee HW, ABSTRACT This therapeutic strategy is associated with Byun SJ, et al. Neoadjuvant Background Neoadjuvant chemoradiation therapy (CRT) downstaging of the tumor, more frequent use chemoradiation alters is a widely used preoperative treatment strategy for of sphincter- preserving procedures by preop- biomarkers of anticancer locally advanced rectal cancer (LARC). However, a few immunotherapy responses in eratively shrinking the tumor, decreased local studies have evaluated the molecular changes caused locally advanced rectal cancer. recurrence and reduced toxicity compared by neoadjuvant CRT in these cancer tissues. Here, we Journal for ImmunoTherapy with postoperative adjuvant chemoradi- aimed to investigate changes in immunotherapy-rela ted of Cancer 2021;9:e001610. ation.1–4 CRT delivers ionizing radiation doi:10.1136/jitc-2020-001610 immunogenic effects in response to preoperative CRT in LARC. directly to target cells, with the goal of causing genetic damage, such as radiation- ► Prepublication history and Methods We analyzed 60 pairs of human LARC tissues additional material is published before and after irradiation from three independent induced DNA double- strand breaks, which online only. To view please visit LARC cohorts, including a LARC patient RNA sequencing are repaired through double-strand break the journal online (http:// dx.
    [Show full text]
  • Offenmüller Et Al. Risk Loci in ALL Gene Location SNP Group And
    Offenmüller et al. Risk loci in ALL Supplemental Table I. Genes and SNPs of the Illumina SNP Cancer Panel, grouped by pathway Genes and SNPs included in the Illumina SNP Cancer Panel. These are described and grouped in major cancer pathways by using information from the NCBI Web pages, the genecards website of the Crown Human Genome Centre & Weizmann Institute of Science. DNA MISMATCH REPAIR, MICROSATELLITE AND CHROMOSOMAL INSTABILITY PATHWAYS Stability genes or caretakers act to keep genetic alterations to a minimum. Depending on the type of damage inflicted on the DNA's double helical structure, a variety of repair strategies have evolved to restore lost information. They include the mismatch repair (MMR), nucleotide-excision repair (NER), and base-excision repair (BER) genes, as well as genes responsible for mitotic recombination and chromosomal segregation. The types of molecules involved and the mechanism of repair that is mobilized depend on the type of damage that has occurred and the phase of the cell cycle that the cell is in. Gene Location SNP Group and function of protein Related disease APEX1 14q11.2-q12 rs1760944 APEX nuclease (multifunctional DNA repair enzyme) 1; major AP endonuclease; rhabdomyosarcoma rs3136814 Apurinic/apyrimidinic (AP) sites occur frequently in DNA molecules by spontaneous hydrolysis, by rs3136820 DNA damaging agents or by DNA glycosylases that remove specific abnormal bases, they are pre- mutagenic lesions that can prevent normal DNA replication; class II AP endonucleases cleave the phosphodiester backbone 5' to the AP site RAD23B 9q31.2 rs1805329 RAD23 homolog B (S. cerevisiae); one of two human homologs; involved in the nucleotide excision melanoma rs1805330 repair (NER) rs1805334 rs1805335 RAD51 15q15.1 rs11852786 RAD51 homolog (RecA homolog, E.
    [Show full text]
  • Universidad Autónoma De Madrid Search for New Susceptibility Genes in Hereditary BRCAX Families with an Apparent Recessive Patt
    Universidad Autónoma de Madrid Departamento de Bioquímica Doctoral Thesis Search for new susceptibility genes in hereditary BRCAX families with an apparent recessive pattern of inheritance using Whole Exome Sequencing Alejandra Tavera Tapia Madrid, 2017 1 Universidad Autónoma de Madrid Facultad de Medicina Departamento de bioquímica Search for new susceptibility genes in hereditary BRCAX families with an apparent recessive pattern of inheritance using Whole Exome Sequencing Doctoral Thesis MSc in Cell Biology Alejandra Tavera Tapia Thesis Directors Dr. Ana Osorio Cabrero Dr. Javier Benítez Ortiz Human Genetics Group Human Cancer Genetics Programme Spanish National Cancer Research Centre 3 This thesis, submitted for the degree of Doctor of Philosophy at the Autonomous University of Madrid, has been elaborated in the Human Cancer Genetics laboratory at the Spanish National Cancer Research Center (CNIO), under the supervision of Dr. Ana Osorio Cabrero and Dr. Javier Benítez Ortíz. This research was supported by the following grants and fellowships: La Caixa/CNIO International PhD Fellowship, 2013-2017: Alejandra Tavera Tapia Boehringer Ingelheim Fonds Travel Fellowship, 2016: Alejandra Tavera Tapia The Spanish Ministry of Economy and Competitiveness (MINECO) SAF2014-57680- R. The Spanish Health Ministry PI12/00070, FEDER funds and H2020 (BRIDGES project, number 634935), and FIS 15/00059 Project “300 exomes to elucidate rare diseases” by National Center for Genomic Analysis (CNAG) CIBERER 9 Summary 11 Only two genes involved in high-risk breast/ovarian cancer hereditary syndrome (HBOC) have been identified, BRCA1 and BRCA2, that do not explain more than 20% of all the HBOC cases. In the last years, Whole Exome Sequencing (WES) has been used to find new high susceptibility genes.
    [Show full text]
  • Exploring the Druggable Space Around the Fanconi Anemia Pathway Using Machine Learning and Mechanistic Models
    bioRxiv preprint doi: https://doi.org/10.1101/647735; this version posted May 24, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Exploring the druggable space around the Fanconi anemia pathway using machine learning and mechanistic models Marina Esteban1, María Peña-Chilet1,2, Carlos Loucera1, Joaquín Dopazo1,2,3,* 1 Clinical Bioinformatics Area. Fundación Progreso y Salud (FPS). CDCA, Hospital Virgen del Rocio. 41013. Sevilla. Spain; 2 Bioinformatics in Rare Diseases (BiER). Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), FPS, Hospital Virgen del Rocío. 41013. Sevilla, Spain; 3 INB-ELIXIR-es, FPS, Hospital Virgen del Rocío, Sevilla, 42013, Spain. * Corresponding author Abstract Background: In spite of the abundance of genomic data, predictive models that describe phenotypes as a function of gene expression or mutations are difficult to obtain because they are affected by the curse of dimensionality, given the disbalance between samples and candidate genes. And this is especially dramatic in scenarios in which the availability of samples is difficult, such as the case of rare diseases. Results: The application of multi-output regression machine learning methodologies to predict the potential effect of external proteins over the signaling circuits that trigger Fanconi anemia related cell functionalities, inferred with a mechanistic model, allowed us to detect over 20 potential therapeutic targets. Conclusions: The use of artificial intelligence methods for the prediction of potentially causal relationships between proteins of interest and cell activities related with disease-related phenotypes opens promising avenues for the systematic search of new targets in rare diseases.
    [Show full text]